[go: up one dir, main page]

AR133423A1 - Vacuna ibv con proteína de espícula dmv/1639 heteróloga - Google Patents

Vacuna ibv con proteína de espícula dmv/1639 heteróloga

Info

Publication number
AR133423A1
AR133423A1 ARP240102027A ARP240102027A AR133423A1 AR 133423 A1 AR133423 A1 AR 133423A1 AR P240102027 A ARP240102027 A AR P240102027A AR P240102027 A ARP240102027 A AR P240102027A AR 133423 A1 AR133423 A1 AR 133423A1
Authority
AR
Argentina
Prior art keywords
dmv
protein
ibv
heterologous
subject
Prior art date
Application number
ARP240102027A
Other languages
English (en)
Inventor
Grace Albanese
Aemro Kassa
Annika Kraemer-Kuehl
Stephane Lemiere
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR133423A1 publication Critical patent/AR133423A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un IBV (virus de la bronquitis infecciosa) que codifica una proteína S (espícula) DMV o fragmento de esta. Además, una composición inmunógena que comprende dicho IBV que codifica una proteína S (espícula) DMV heteróloga o fragmento de esta. Asimismo, métodos para inmunizar un sujeto, que comprenden administrar a dicho sujeto la composición inmunógena de la presente invención. Además, métodos para tratar o prevenir signos clínicos causados por IBV en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de una composición inmunógena de acuerdo con la presente invención.
ARP240102027A 2023-08-03 2024-07-31 Vacuna ibv con proteína de espícula dmv/1639 heteróloga AR133423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363517502P 2023-08-03 2023-08-03

Publications (1)

Publication Number Publication Date
AR133423A1 true AR133423A1 (es) 2025-09-24

Family

ID=92593086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102027A AR133423A1 (es) 2023-08-03 2024-07-31 Vacuna ibv con proteína de espícula dmv/1639 heteróloga

Country Status (3)

Country Link
US (1) US20250064920A1 (es)
AR (1) AR133423A1 (es)
WO (1) WO2025027551A2 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP3873516A1 (en) * 2018-10-31 2021-09-08 Boehringer Ingelheim Vetmedica GmbH 4/91 ibv vaccine with heterologous spike protein
CN120330146A (zh) 2018-10-31 2025-07-18 勃林格殷格翰动物保健有限公司 具有异源刺突蛋白的h52 ibv疫苗
MX2021013743A (es) 2019-05-10 2021-12-10 Boehringer Ingelheim Vetmedica Gmbh Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2023003198A (es) 2020-09-22 2023-04-13 Univ Georgia Aislado atenuado de la cepa delmarva/1639 (dmv1639) de virus de la bronquitis infecciosa.
EP4436601A4 (en) * 2021-11-23 2026-01-07 Wisconsin Alumni Res Found Gene-modified vaccines against avian coronaviruses and their methods of use

Also Published As

Publication number Publication date
WO2025027551A2 (en) 2025-02-06
WO2025027551A3 (en) 2025-05-30
US20250064920A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
WO2022043551A3 (en) Multivalent nucleic acid based coronavirus vaccines
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
PH12019500592A1 (en) New swine influenza vaccine
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX381132B (es) Vacuna contra parvovirus porcino.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
CO2019013220A2 (es) Virus oncolíticos y método
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
MX2021014226A (es) Arn terapeutico para cancer de ovario.
AR133423A1 (es) Vacuna ibv con proteína de espícula dmv/1639 heteróloga
AR123998A1 (es) Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
CO2022007006A2 (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar
MX2025012040A (es) Vacuna contra el vih
AR122262A1 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
AR132427A1 (es) Vacuna contra el vih
AR127807A1 (es) Vacuna contra el coronavirus
AR131707A1 (es) Composiciones farmacéuticas para la administración de antígenos de glicoproteína c, glicoproteína d y glicoproteína e del virus del herpes simple y métodos relacionados
AR121653A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
AR122208A1 (es) Anticuerpos neutralizantes contra coronavirus asociado a sars